Yassine’s career in neuroscience began with earning his Ph.D. and quickly advancing through impactful roles in the pharmaceutical and biotechnology sectors. His initial years at Sanofi-Aventis were marked by the creation of innovative rodent models for chemo-induced neuropathies. He then moved to Neorphys, where he led biological and pharmacological research activities focused on discovering novel analgesics.
At ANS Biotech, Yassine spent 13 years as Head of the in vivo Pharmacology Laboratory. In this role, he managed both fee-for-service activities and R&D projects in pain pharmacology, significantly advancing the company’s research capabilities and reputation. His leadership in developing and implementing sophisticated pharmacological models has been instrumental in advancing pain research.
Currently serving as Chief Business Officer at ANS Biotech, Yassine is responsible for driving the company’s business strategies. His dual expertise in scientific research and commercial operations enables him to promote strategic growth and cultivate key partnerships. Yassine’s deep knowledge of neuroscience, coupled with his adept leadership and business insight, ensures that ANS Biotech continues to thrive and innovate in the competitive biotech landscape.